ArticleInternational journal of radiation oncology, biology, physics2026
Local Control With Reduced-Dose Radiation Therapy for High-Risk Neuroblastoma: Results From a Prospective Clinical Trial.
Article in International journal of radiation oncology, biology, physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systematic Targeting of GD2-Positive Neuroblastoma Tumors With a Photooncolytic Phage Nanovector Platform.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeLittle is known about local control, toxicity, and survival outcomes associated with reduced-dose radiation therapy (RT) for high-risk neuroblastoma (HR-NB). METHODS AND MATERIALS: In this prospective pilot study, eligible patients had HR-NB with a gross total resection (no tumor evident on postsurgery CT or MRI) of the primary site after induction systemic therapy. Patients were treated with 15 or 18 Gy to the primary site in 1.5 Gy fractions delivered twice daily. The primary outcome was to assess local failure (LF) at the primary site. The secondary outcomes included overall survival (OS), event-free survival (EFS), distant-metastasis-free survival (DMFS), and acute toxicity from RT.
resultsA total of 78 patients were enrolled between 2014 and 2023 at a single institution. Median follow-up from time of RT was 35 months (interquartile range [IQR] 19-67 months). Median age at the time of RT was 3.8 years (IQR, 2.4-5.6). Forty-seven patients (60%) received proton RT, 53 (68%) received 15 Gy, and 25 (32%) received 18 Gy. Three patients experienced LF at the primary site, all at 15 Gy. At 1 and 5 years post-RT, the rate of LF was 2.6 and 3.9%, respectively. There was no significant difference in the risk of LF by MYCN-amplification status (P = .5). There was no significant difference in OS, EFS, or DMFS between the 15 Gy and 18 Gy cohorts (P = .95, P = .45, and P = .45, respectively). Thirty-two patients (41%) experienced acute toxicity, which included grade 1 to 2 fatigue, nausea, and decreased appetite.
conclusionsFor patients with HR-NB who have a GTR of the primary site, reduced-dose RT of 15 to 18 Gy is associated with an approximately 96% local control rate with negligible acute toxicity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.